Abstract
Eribulin mesylate (Halaven; Eisai) — a synthetic analogue of the marine natural product halichondrin B that interferes with microtubule dynamics — was approved in November 2010 by the US Food and Drug Administration for the treatment of metastatic breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nature Rev. Drug Discov. 9, 790–803 (2010).
Jackson, K. L. et al. The halichondrins and E7389. Chem. Rev. 109, 3044–3079 (2009).
Towle, M. J. et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013–1021 (2001).
Seletsky, B. M. et al. Structurally simplified macrolactone analogues of halichondrin B. Bioorg. Med. Chem. Lett. 14, 5547–5550 (2004).
Kuznetsov, G. et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 64, 5760–5766 (2004).
Jordan, M. A. et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086–1095 (2005).
Dabydeen, D. A. et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol. Pharmacol. 70, 1866–1875 (2006).
US Food and Drug Administration. FDA labelling information — Halaven. FDA website [online], http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf, (2010).
Cortes, J. et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 28, 3922–3928 (2010).
Twelves, C. et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin. Breast Cancer 10, 160–163 (2010).
American Cancer Society. Cancer facts and figures 2010. ACS website [online], http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-026238.pdf, (2010).
Beslija, S. et al. Third consensus on medical treatment of metastatic breast cancer. Ann. Oncol. 20, 1771–1785 (2009).
Dufresne, A. et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res. Treat. 107, 275–279 (2008).
Moreno-Aspitia, A. & Perez, E. A. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin. Proc. 84, 533–545 (2009).
Onozuka, M. Japan Equity Research (26 Jan 2011).
Sakai, F. & Tateno, T. Credit Suisse Asia Pacific/Japan Equity Research (26 Jan 2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Huyck, T., Gradishar, W., Manuguid, F. et al. Eribulin mesylate. Nat Rev Drug Discov 10, 173–174 (2011). https://doi.org/10.1038/nrd3389
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3389